The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17.
C. J. O'Callaghan
No relevant relationships to disclose
D. Tu
No relevant relationships to disclose
C. S. Karapetis
No relevant relationships to disclose
H. Au
No relevant relationships to disclose
M. J. Moore
No relevant relationships to disclose
N. C. Tebbutt
No relevant relationships to disclose
M. G. Trudeau
No relevant relationships to disclose
T. J. Price
No relevant relationships to disclose
D. Yip
No relevant relationships to disclose
D. J. Jonker
No relevant relationships to disclose